TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug
The FDA approves TG Therapeutics (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch…
25,050$
-0,32%
Echtzeit-Aktienkurs TG Therapeutics
Bid:
Ask:
Nachrichten zur TG Therapeutics Aktie
Thinking about buying stock in Quotient, TAL Education, Core Scientific, TG Therapeutics, or Rivian Automotive?
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QTNT, TAL, CORZ, TGTX, and RIVN. To…
Form 8-K TG THERAPEUTICS, INC. For: Dec 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics Up 29% on FDA Approval of MS Drug Briumvi
TG Therapeutics Up 29% on FDA Approval of MS Drug Briumvi...…
FDA Approves TG Therapeutics Inc.s MS Drug Briumvi
FDA Approves TG Therapeutics Inc.'s MS Drug Briumvi...…
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can…
TG Therapeutics spikes as FDA approves multiple sclerosis therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Can TG Therapeutics (TGTX) Climb 155% to Reach the Level Wall Street Analysts Expect?
The mean of analysts price targets for TG Therapeutics (TGTX) points to a 154.7% upside in the stock. While this…
Why Shares of TG Therapeutics Climbed 59.9% This Week
The company got a big bump from the FDA....…
TG Therapeutics jumps 56% amid FDA labeling talks for multiple sclerosis therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics Stock Jumps on Materially Narrowed 3Q Loss
TG Therapeutics Stock Jumps on Materially Narrowed 3Q Loss...…
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Conference call to be held today, November 10, 2022 at 8:30 AM ET Conference call to be held today, November…
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of…